IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study
Wu, Depei1; Du, Xin2; Jin, Jie3; Xiao, Zhijian4,5; Shen, Zhixiang6; Shao, Zonghong7; Li, Xiao8; Huang, Xiaojun9; Liu, Ting10; Yu, Li11; Li, Jianyong12; Chen, Baoan13; He, Guangsheng1; Cai, Zhen3; Liang, Hongchuang14; Li, Jigang14; Ruan, Changgeng1
关键词Chinese population Decitabine Hematology Myelodysplastic syndrome (MDS) Oncology Phase 3b
刊名ADVANCES IN THERAPY
2015-11-01
DOI10.1007/s12325-015-0263-8
32期:11页:1140-1159
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, Research & Experimental ; Pharmacology & Pharmacy
资助者Xian-Janssen Pharmaceutical Ltd. China ; Xian-Janssen Pharmaceutical Ltd. China (a company of Johnson Johnson) ; Xian-Janssen Pharmaceutical Ltd. China ; Xian-Janssen Pharmaceutical Ltd. China (a company of Johnson Johnson)
研究领域[WOS]Research & Experimental Medicine ; Pharmacology & Pharmacy
关键词[WOS]CHRONIC MYELOGENOUS LEUKEMIA ; INTERNATIONAL WORKING GROUP ; ACUTE MYELOID-LEUKEMIA ; RESPONSE CRITERIA ; 5-AZA-2&prime ; -DEOXYCYTIDINE DECITABINE ; HYPOMETHYLATING AGENT ; SCORING SYSTEMS ; MULTICENTER ; MANAGEMENT ; DIAGNOSIS
英文摘要

The objective of this study was to evaluate the efficacy and safety of decitabine in Chinese patients with myelodysplastic syndrome (MDS).

Patients (a parts per thousand yen18 years) who had a de novo or secondary MDS diagnosis according to French-American-British classification and an International Prognostic Scoring System score a parts per thousand yen0.5 were enrolled and randomized (1:1) to one of two decitabine regimens: 3-day treatment (3-h intravenous infusion of 15 mg/m(2) given every 8 h for three consecutive days/cycle/6 weeks) or 5-day treatment (1-h intravenous infusion of 20 mg/m(2) once daily on days 1-5/cycle/4 weeks). After a minimum of 30 patients were assigned to 3-day schedule, the remaining were assigned to the 5-day schedule. The primary efficacy endpoint was the overall response rate (ORR). Secondary outcome measures included hematologic improvement (HI), cytogenetic response rate, the time to acute myeloid leukemia (AML) progression, and overall survival (OS).

In total, 132 of 135 enrolled patients (3-day treatment, n = 36; 5-day treatment, n = 99) discontinued treatment (major reasons included patient withdrawal/lack of efficacy, n = 48; adverse events, n = 23; and disease progression, n = 22). During the study, 35 of 132 (26.5%) patients from the intent-to-treat (ITT) group achieved significant (P < 0.001) ORR [3-day group (n = 10, 29.4%), P = 0.003; 5-day group (n = 25, 25.5%), P < 0.001]. The HI rate was similar between the 3-day (47.1%) and 5-day groups (48.0%). Cytogenetic response was achieved in 20 of the 30 (66.7%) patients who had a baseline cytogenetic abnormality. Fifty-three (40.2%) AML transformations or deaths occurred and the median AML-free survival time was 23.8 months for all patients from the ITT set; 24-month OS rate was 48.9%. Adverse events of myelosuppression-related disorders (85.6%) and infections (43.2%) were commonly reported.

Decitabine treatment was efficacious in Chinese patients with MDS with its safety profile comparable to the global studies of decitabine conducted to date.

Xian-Janssen Pharmaceutical Ltd. China (a company of Johnson & Johnson).

ClinicalTrials.gov identifier, NCT01751867.

语种英语
资助者Xian-Janssen Pharmaceutical Ltd. China ; Xian-Janssen Pharmaceutical Ltd. China (a company of Johnson Johnson) ; Xian-Janssen Pharmaceutical Ltd. China ; Xian-Janssen Pharmaceutical Ltd. China (a company of Johnson Johnson)
WOS记录号WOS:000365796400008
引用统计
被引频次:5[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/63974
专题北京大学第二临床医学院
作者单位1.Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China
2.Blood Dis Hosp, Tianjin, Peoples R China
3.Tianjin Med Univ, Gen Hosp, Tianjin, Peoples R China
4.Shanghai 6th Peoples Hosp, Shanghai, Peoples R China
5.Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China
6.Sichuan Univ, West China Hosp, Chengdu 610064, Peoples R China
7.Xian Janssen Pharmaceut Ltd, Beijing, Peoples R China
8.Soochow Univ, Affiliated Hosp 1, Suzhou, Jiangsu, Peoples R China
9.Zhejiang Univ, Coll Med, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China
10.Chinese Acad Med Sci, Inst Hematol, Tianjin, Peoples R China
11.Shanghai Jiao Tong Univ, Coll Med, Affiliated Ruijin Hosp, Shanghai 200030, Peoples R China
12.Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
13.Nanjing Med Univ, Jiangsu Prov Hosp, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China
14.Southeast Univ, Zhongda Hosp, Nanjing, Jiangsu, Peoples R China
推荐引用方式
GB/T 7714
Wu, Depei,Du, Xin,Jin, Jie,et al. Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study[J]. ADVANCES IN THERAPY,2015,32(11):1140-1159.
APA Wu, Depei.,Du, Xin.,Jin, Jie.,Xiao, Zhijian.,Shen, Zhixiang.,...&Ruan, Changgeng.(2015).Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study.ADVANCES IN THERAPY,32(11),1140-1159.
MLA Wu, Depei,et al."Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study".ADVANCES IN THERAPY 32.11(2015):1140-1159.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wu, Depei]的文章
[Du, Xin]的文章
[Jin, Jie]的文章
百度学术
百度学术中相似的文章
[Wu, Depei]的文章
[Du, Xin]的文章
[Jin, Jie]的文章
必应学术
必应学术中相似的文章
[Wu, Depei]的文章
[Du, Xin]的文章
[Jin, Jie]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。